Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study

Published:2024-07 Issue: Volume:73 Page:102655
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Passeron Thierry^ORCID,Ezzedine Khaled^ORCID,Hamzavi Iltefat,van Geel Nanja^ORCID,Schlosser Bethanee J.,Wu Xiaoqiang,Huang Xiaohong,Soliman Ahmed M.,Rosmarin David,Harris John E.,Camp Heidi S.^ORCID,Pandya Amit G.^ORCID

Funder

AbbVie

Publisher

Elsevier BV

Reference28 articles.

1. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA;Bibeau;J Eur Acad Dermatol Venereol,2022

2. Prevalence of vitiligo among adults in the United States;Gandhi;JAMA Dermatol,2022

3. Janus kinase inhibitors in the treatment of vitiligo: a review;Qi;Front Immunol,2021

4. Comorbidity burden among patients with vitiligo in the United States: a large-scale retrospective claims database analysis;Ezzedine;Dermatol Ther (Heidelb),2023

5. The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes;Picardo;J Eur Acad Dermatol Venereol,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic inhibition of the JAK-STAT pathway in the treatment of inflammatory bowel disease;Cytokine & Growth Factor Reviews;2024-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP